This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): BIIB019, anti CD25, Zenapax, R35, DAC HYP, Daclizumab High-Yield Process
Description: Daclizumab binds to the interleukin-2 (IL-2) receptor on immune system cells known as T cells. IL-2 is a lymphokine, one of the substances released by cells as part of the immune response that occurs in autoimmune diseases and often following organ transplants. IL-2 stimulates T cells to divide and participate in an immune response. Daclizumab blocks the binding of IL-2 to its receptor on T cells, suppressing an immune response by inhibiting the proliferation of activated T cells.
Revenue splits for this drug are BioMedTracker estimates.
PDL and Roche
In 1989, Roche acquired the worldwide rights to daclizumab. In October 2003, Roche resold to PDL all rights to daclizumab, except in transplantation, until 2007 when PDL will have the option to re-acquire the transplantation rights as well.
In November 2005, Roche and Protein Design Labs announced an expansion to their partnership to co-develop and commercialize daclizumab for organ transplant patients on long-term, maintenance therapy.
Under the terms of this agreement, PDL will receive a $10 million upfront payment and may be eligible to receive payments up to $145 million in milestones. Roche will continue to manufacture and promote daclizumab exclusively on a worldwide basis. Roche and PDL will share equally global development costs, and PDL has the option to co-promote subcutaneous daclizumab for transplant maintenance in the United States. Outside the United States, PDL will receive...See full deal structure in Biomedtracker
Partners: AbbVie Inc. PDL BioPharma, Inc. UCB SA
Additional information available to subscribers only: